Bromazine or bromodiphenhydramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H20BrNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T032BI7727, chemically known as ethanamine, 2-((4-bromophenyl)phenylmethoxy)-n,n-dimethyl- but generally known as bromazine, which bears US NIH Compound Identifier 2444. Bromazine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05908MIG. The term BROMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules bromazine in its Anatomical Therapeutic Chemical (ATC) Classification. BROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Bromazine or bromodiphenhydramine bears US NLM identifiers UMLS ID C0054120 and NCI Concept Code C61654. SMILES: BRC1CCC(C(OCCN(C)C)C2CCCCC2)CC1.